Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

BACKGROUND: Mucosal melanoma is an aggressive melanoma subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination with toripalimab, a humanized IgG4 mAb against PD-1, showed a promising response rate in patients with metastatic mucosal melanoma (MM) in a ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siming, Wu, Xiaowen, Yan, Xieqiao, Zhou, Li, Chi, Zhihong, Si, Lu, Cui, Chuanliang, Tang, Bixia, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Dai, Jie, Kong, Yan, Tang, Xiongwen, Feng, Hui, Yao, Sheng, Flaherty, Keith T, Guo, Jun, Sheng, Xinan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066368/
https://www.ncbi.nlm.nih.gov/pubmed/35193932
http://dx.doi.org/10.1136/jitc-2021-004036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066368/
https://www.ncbi.nlm.nih.gov/pubmed/35193932
http://dx.doi.org/10.1136/jitc-2021-004036

Ejemplares similares